Sign up USA
Proactive Investors - Run By Investors For Investors

Aphria reports higher 1Q fiscal first quarter revenue and looks ahead to cannabis legalization in Canada

Legalization of cannabis is a major inflection point for the industry in Canada
Cannabis sign
Aphria is involved in the low-cost production of safe, clean and pure pharmaceutical-grade cannabis

Canadian cannabis company Aphria Inc (TSX:APH) (OTCQB:APHQF) reported on Friday higher fiscal first-quarter revenues from strong sales as the company looked forward to the looming legalization of marijuana in the country next week.

The company said in a statement revenue for the period ending on August 31, 2018, reached C$13,292, 10% higher than the prior quarter's C$12,026 and 117% higher than the same period last year.

"As we long maintained, the legalization of adult-use cannabis in Canada is a major inflection point for the industry and all licensed producers, Aphria included," said company CEO Vic Neufeld.

Neufeld said the company "continued to ramp up our production capabilities" and moved "forward aggressively with the implementation of our automation infrastructure, which is expected to streamline production over the medium to longer terms."

"We believe the automation investment in particular will provide Aphria with a significant competitive advantage and further our industry-leading low-cost structure," he added.

Shares of Aphria in Canada was off 0.46% on Friday to C$19.61. In New York though, they were up 0.73% to $15.21.

READ: Aphria partners with Rapid Dose Therapeutics to develop dissolving oral cannabis strips

Among the company highlights Aphira pointed to are higher sales which "was driven primarily by increased wholesale orders, accounting for 313 kgs," a statement said.

Aphria said Canadian-based production capacity is on schedule to reach 255,000 kgs per annum. 

The company has supply agreements with every province in Canada and the Yukon Territory, ensuring access to Aphria products for 99.8% of the Canadian population. The company a representative agreement to be the exclusive sales representative for We Grow BC Ltd.

Aphria has launched the company's initial portfolio of adult-use brands: Solei Sungrown Cannabis, RIFF, Good Supply, and Goodfields. It has successfully divested all US cannabis assets and closed on a deal for a common share offering during the period to raise net proceeds of more than C$245 million

Aphria is a cannabis company which is involved in the low-cost production of safe, clean and pure pharmaceutical-grade cannabis. The company is based in Lemington, Ontario. 

Reporting by Rene Pastor, contactable on [email protected]

View full APH profile View Profile

Aphria Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use